@article{oai:kanazawa-u.repo.nii.ac.jp:00056417, author = {前田, 大地 and Uni, Masahiro and Yoshimi, Akihide and Maki, Hiroaki and Maeda, Daichi and Nakazaki, Kumi and Nakamura, Fumihiko and Fukayama, Masashi and Kurokawa, Mineo}, issue = {6}, journal = {International Journal of Clinical and Experimental Pathology}, month = {May}, note = {We report here a 47-year-old male with the diagnosis of high-grade B-cell lymphoma and hemophagocytosis accompanying disseminated intravascular coagulation (DIC). Lymphoma-associated hemophagocytic syndrome (LAHS) is a life-threatening disorder, and LAHS secondary to B-cell lymphoma is relatively rare compared to that secondary to T- or NK/T-cell lymphoma in Western countries. T- or NK/T-cell LAHS is sometimes combined with DIC, which makes patients' outcomes even worse, but few reports of B-cell LAHS accompanying DIC has been published so far. We successfully treated a patient with this condition with recombinant thrombomodulin (rTM), a novel agent for DIC. We believe that rTM is a therapeutic option in cases with B-cell LAHS accompanying DIC., 金沢大学医薬保健研究域医学系}, pages = {1190--1194}, title = {Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation}, volume = {6}, year = {2013} }